Coreline Soft, a medical AI company, announced on the 26th that it will participate in the Radiological Society of North America (RSNA) 2024 meeting, held from December 1 to 5 at McCormick Place in Chicago, USA.

This year's RSNA theme is "Building Intelligent Connections," and Coreline Soft will share its extensive development in AI diagnostic products, notably the AVIEW suite, not just in diagnostics but also in IT technologies and workflow improvements with key opinion leaders (KOLs) in the U.S. hospital and chest imaging sectors at booth #4949.

The booth will include demonstrations of △AVIEW LCS, an automatic lung nodule analysis software, △AVIEW CAC, an automatic coronary artery calcification analysis software, △RT ACS, an automatic organ segmentation software, and △AVIEW Modeler, a medical imaging 3D modeling and printing software.

Additionally, a variety of papers related to AVIEW will be presented. These include research on AI technology for automatic classification of lung clusters, a significant marker in lung cancer screening; content-based image retrieval technology enhancing inter-reader agreement in CT pattern classification for idiopathic pulmonary fibrosis (IPF); a study on the prognostic value of technology distinguishing and quantifying pulmonary arteries and veins in non-contrast chest CT using deep learning; and a study on predicting forced vital capacity (FVC) in pulmonary fibrosis patients using quantitative chest CT data, verified across multiple centers. Coreline Soft employees authored four of these papers, and many other studies utilizing AVIEW were presented.

James Lee, North America Branch head of Coreline Soft, stated, "We plan to share real-world application cases of AVIEW across various thoracic diseases that aid in comprehensive and accurate diagnoses." He added that they aim to continually demonstrate the reliability and clinical efficacy of imaging diagnostic technologies, gaining trust from global hospitals and companies based on recent experiences at major conferences like GOLD COPD and various research achievements.
Meanwhile, Coreline Soft's entry into the U.S. medical market shows promising signals. In the first half of this year, they sold AVIEW LCS Plus, a simultaneous diagnostic product for early detection of lung cancer, emphysema, and coronary artery calcification (CAC), to UMass Memorial Medical Center, one of Massachusetts's Top 5 hospitals. In early November, they sold three major products simultaneously to the Temple Lung Center under Temple University Hospital, which leads in lung disease treatment. The company is expanding its collaboration beyond traditional radiology departments to KOLs in pulmonology, showing significant outcomes.

At the RSNA 2024 booth, Coreline Soft will engage in diverse business discussions with global medical device companies. Topics will include △Precision Medicine, contributing to personalized treatment solutions by analyzing patient clinical data and △Clinical research support, optimizing clinical trials, and increasing the success rates of new drug development through AI and extensive medical data utilization. The company plans active global business discussions, including meetings on workflow improvement collaborations with institutions like Mayo Clinic Rochester and Northwestern Medicine, associated with Northwestern University Hospital.
Given Coreline's collaborative network with leading KOLs in imaging and respiratory fields and its active engagement with key hospitals, significant achievements are expected to become evident starting next year.

Dan Yoo 다른기사 보기